A $1.5million (£950,000) community development programme in Africa has been unveiled by GlaxoSmithKline.
The pharmaceuticals firm is spending the money on micro-credit and anti-malaria schemes across the continent and claims that in the course of the next three years nearly two million people in seven countries will benefit.
